Asymptomatic herpes simplex virus (HSV) shedding was described in a cohort of human immunodeficiency virus (HIV)-infected women, and the association of HSV shedding with changes in plasma HIV RNA load was investigated. Genital, rectal, and oral swabs were obtained daily during a 4-week period for polymerase chain reaction and culture, and concomitant plasma specimens were drawn 3 times weekly for determination of HIV RNA load. During the study, 70% and 79% of subjects shed HSV from the oral cavity and genital area, respectively. Shedding of HSV occurred for a mean of 3.2 days for oral shedding and 5.4 days for genital shedding. Mean plasma HIV RNA loads during periods of HSV shedding and nonshedding and for periods 3 days after the cessation of shedding were compared; no significant differences were found (P=.74). In women who shed HSV, as evaluated by detection of virus, plasma HIV RNA load did not fluctuate with HSV shedding.

Download full-text PDF

Source
http://dx.doi.org/10.1086/322654DOI Listing

Publication Analysis

Top Keywords

hsv shedding
16
hiv rna
16
plasma hiv
12
rna load
12
shedding
9
herpes simplex
8
simplex virus
8
shedding plasma
8
human immunodeficiency
8
immunodeficiency virus
8

Similar Publications

Herpes Simplex virus (HSV) is the cause of genital herpes and no prophylactic treatment is currently available. Replication-incompetent adenoviral vectors are potent inducers of humoral and cellular immune responses in humans. We have designed an adenoviral vector type 35 (Ad35)-based vaccine encoding the HSV-2 major surface antigen gD2 (Ad35.

View Article and Find Full Text PDF

Herpes simplex virus (HSV) infection has worldwide public health concerns and lifelong medical impacts. The standard therapy, acyclovir, has limited efficacy in preventing HSV subclinical virus shedding, and drug resistance occurs in immunocompromised patients, highlighting the need for novel therapeutics. HSV infection manifests in the skin epidermal layer, but current drug discovery utilizes Vero cells and fibroblasts monolayer cultures, capturing neither relevance nor tissue environment.

View Article and Find Full Text PDF

Herpes simples virus 1 (HSV-1) keratitis is a major cause of blindness globally. During primary infection, HSV-1 travels to the trigeminal ganglia and establishes lifelong latency. Although some treatments can reduce symptom severity and recurrence, there is no cure for HSV-1 keratitis.

View Article and Find Full Text PDF

Depot-medroxyprogesterone acetate (DMPA) and Norethisterone Enanthate (NET-EN) are progestin-only injectable contraceptives widely used by women in sub-Sharan Africa, where incidence of HIV-1 and HSV-2 infection remains high. Studies indicate that DMPA usage can increase the risk of HSV-2 infection, but limited data indicate no increased risk with use of NET-EN. We therefore investigated the effects of NET-EN and DMPA on susceptibility to vaginal HSV-2 infection in ovariectomized (OVX) mice and effects on immune responses, particularly in the vaginal tract (VT).

View Article and Find Full Text PDF

Genital Herpes: Rapid Evidence Review.

Am Fam Physician

November 2024

Eglin Air Force Base Family Medicine Residency Program in Florida.

Article Synopsis
  • - Genital herpes, caused by herpes simplex virus (HSV) types 1 or 2, is a lifelong sexually transmitted infection affecting over 500 million people globally, with no available vaccines for prevention.
  • - It is characterized by painful genital lesions and flu-like symptoms; diagnosis is typically made through laboratory tests like PCR or viral culture.
  • - Treatment includes antiviral medications to manage outbreaks and reduce transmission, and pregnant individuals with a history of genital herpes are advised to start antiviral therapy at 36 weeks and may require a cesarean section if lesions are present.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!